A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Inclusion Criteria

• Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stablepsoriasis is defined as no morphology changes or significant flares of diseaseactivity in the opinion of the investigator.

• Deemed by the investigator to be a candidate for phototherapy or systemic therapy.

• ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1

• Dermatology Life Quality Index (DLQI) score > 5 at the Screening Visit and Day 1

• Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1

Exclusion Criteria:

Target Disease Exceptions:

• Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar onlyinvolvement or drug-induced psoriasis) at Screening Visit or Day 1

Other protocol-defined inclusion/exclusion criteria apply.